Cargando…

Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis

Background: Polyethylene glycol interferon alpha (PEG-IFN-α) is the most frequently used pharmacotherapeutic approach in patients infected with hepatitis B virus (HBV). Numerous studies have reported that interleukin-28B (IL-28B) genetic polymorphisms are related to the therapeutic efficacy of PEG-I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ying, Sang-Yu, Hu, Yao-Ren, Gao, Guo-Sheng, Lou, Ke-Hong, Huang, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298999/ https://www.ncbi.nlm.nih.gov/pubmed/34307418 http://dx.doi.org/10.3389/fmed.2021.691365

Ejemplares similares

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
por: Pouresmaeeli, Mahdiyar, et al.
Publicado: (2015)

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
por: Jeong, Seok Hoo, et al.
Publicado: (2012)

Role of interleukin-21 and interleukin-21 receptor polymorphisms in the treatment of HBeAg-positive chronic hepatitis B patients with peginterferon
por: Wang, Xia, et al.
Publicado: (2018)

Interleukin-28B polymorphisms and hepatitis C virus clearance
por: Chayama, Kazuaki, et al.
Publicado: (2013)

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis
por: Druyts, Eric, et al.
Publicado: (2012)

Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection
por: Alestig, Erik, et al.
Publicado: (2011)

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
por: Miyamura, Tatsuo, et al.
Publicado: (2012)

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C
por: Yan, Zehui, et al.
Publicado: (2012)

Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus
por: Kalantari, Hamid, et al.
Publicado: (2014)

Role of Interleukin-28B Genetic Polymorphisms in Korean Patients with Hepatitis C Virus Infection
por: Kil, Ho, et al.
Publicado: (2014)

Do interleukin-28B single nucleotide polymorphisms influence the natural history of chronic hepatitis B?
por: Martín-Carbonero, L, et al.
Publicado: (2010)

No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
por: Heo, Nae-Yun, et al.
Publicado: (2014)

Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response
por: Asahina, Yasuhiro, et al.
Publicado: (2013)

Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment
por: Gozdas, Hasan Tahsin, et al.
Publicado: (2015)

Expression Pattern of Cytokines in Patients with Chronic Hepatitis B Receiving PEGinterferon Therapy
por: Chen, Shao-Long, et al.
Publicado: (2023)

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials
por: Li, Wen-cong, et al.
Publicado: (2011)

Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
por: Yang, Zongguo, et al.
Publicado: (2013)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus
por: Kim, Yu Jin, et al.
Publicado: (2011)

Interleukin 28B Gene Polymorphism and Association with Chronic Hepatitis C Therapy Results in Latvia
por: Tolmane, Ieva, et al.
Publicado: (2012)

Association of Hepatitis C Virus Infection and Interleukin-28B Gene Polymorphism in Chinese Children
por: Wu, Rong-Rong, et al.
Publicado: (2014)

The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study
por: El Raziky, Maissa, et al.
Publicado: (2013)

Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C
por: Jiménez-Sousa, María A, et al.
Publicado: (2013)

Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C
por: Wang, Liang-Jen, et al.
Publicado: (2016)

Efficacy of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV: Interpretation of Results and Future Prospects
por: Khedmat, Hossein, et al.
Publicado: (2010)

No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B
por: Wei, Lai, et al.
Publicado: (2018)

Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment
por: Nakamura, Masato, et al.
Publicado: (2013)

The Comparative Efficacy and Safety of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV Infection: A Meta-Analysis
por: Alavian, Seyed Moayed, et al.
Publicado: (2010)

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4
por: Domagalski, Krzysztof, et al.
Publicado: (2013)

Hepatitis B Surface Antigen (HBsAg) Kinetics in Chronic Hepatitis B Patients during Peginterferon Treatment
por: Wang, Kaifa, et al.
Publicado: (2020)

Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
por: Lok, Anna S., et al.
Publicado: (2019)

Association of LIN28B polymorphisms with chronic hepatitis B virus infection
por: Han, Qunying, et al.
Publicado: (2020)

Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
por: Bi, Jingfeng, et al.
Publicado: (2017)

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C
por: Yu, Jiao, et al.
Publicado: (2022)

Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B
por: van Campenhout, Margo J. H., et al.
Publicado: (2020)

Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B
por: Brakenhoff, Sylvia M, et al.
Publicado: (2022)

Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins
por: Bellanti, Francesco, et al.
Publicado: (2015)

A Fast and Cost-Effective Method for Identifying a Polymorphism of Interleukin 28B Related to Hepatitis C
por: Ferreira, Camila da Silva, et al.
Publicado: (2013)

Prevalence of interleukin-28B single nucleotide polymorphism genotypes in patients with hepatitis C infection in Isfahan, Iran
por: Minakari, Mohammad, et al.
Publicado: (2016)

Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis
por: Gatselis, Nikolaos K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_knbj19fpc9i82q3mtngfnned8g